SCHEMBL18292467

SCHEMBL18292467

CC1CCCCN1C(=O)CSc1nnc(-c2ccncc2)n1-c1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.66
HPGD P15428 4/20 0.66
KDM4E B2RXH2 3/20 0.66
THRB P10828 1/20 0.66
HTT P42858 3/20 0.55
NPC1 O15118 1/20 0.55
LMNA P02545 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.54
KMT2A Q03164 2/20 0.52
MAPT P10636 3/20 0.51
RGS12 O14924 1/20 0.51
PTK2 Q05397 1/20 0.51
RECQL P46063 1/20 0.51
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18292678 0.85 HTT (0.68) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL18292112 0.76 HTT (0.55) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL18292384 0.75 CYP2C9 (0.69) ALDH1A1KDM4EHTTSMN1; SMN2MAPT
SCHEMBL20011475 0.73 HPGD (0.78) ALDH1A1HPGDKDM4ETHRBLMNA
SCHEMBL18556573 0.73 HPGD (1.00) ALDH1A1HPGDKDM4ETHRBKMT2A
SCHEMBL11919994 0.72 CYP3A4 (0.66) ALDH1A1HPGDHTTSMN1; SMN2KMT2A
SCHEMBL6213562 0.72 ALPG (0.64) ALDH1A1HPGDKDM4ELMNAMAPT
SCHEMBL6210228 0.72 MAPT (0.71) ALDH1A1THRBLMNAMAPTPTK2
SCHEMBL13831342 0.71 MAPT (0.75) ALDH1A1LMNAMAPTPTK2TP53
SCHEMBL18292430 0.71 L3MBTL1 (0.72) ALDH1A1HPGDHTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D ALDH1A1 2638/4885HPGD 3887/4885KDM4E 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.